Dimensional Fund Advisors LP Tcr2 Therapeutics Inc. Transaction History

Dimensional Fund Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.0 - $1.62 $38,904 - $63,024	-38,904 Reduced 18.52%	171,214 $256,000
Q4 2022 Feb 09, 2023	SELL	$0.83 - $1.44 $97,798 - $169,675	-117,830 Reduced 35.93%	210,118 $210,000
Q3 2022 Nov 10, 2022	BUY	$1.86 - $3.75 $365,592 - $737,081	196,555 Added 149.59%	327,948 $590,000
Q2 2022 Aug 12, 2022	BUY	$2.11 - $2.94 $15,702 - $21,879	7,442 Added 6.0%	131,393 $381,000
Q1 2022 May 13, 2022	SELL	$2.4 - $4.71 $6,204 - $12,175	-2,585 Reduced 2.04%	123,951 $342,000

Q4 2021 Feb 09, 2022	SELL	$4.58 - $8.34 $48,763 - $88,795	-10,647 Reduced 7.76%	126,536 $590,000
Q3 2021 Nov 12, 2021	SELL	$8.44 - $18.35 $2.6 Million - $5.66 Million	-308,632 Reduced 69.23%	137,183 $1.17 Million
Q2 2021 Aug 12, 2021	BUY	$16.41 - $24.71 $1.56 Million - $2.35 Million	95,131 Added 27.13%	445,815 $7.32 Million
Q1 2021 May 14, 2021	BUY	$20.38 - $34.07 $4.81 Million - $8.05 Million	236,154 Added 206.19%	350,684 $7.74 Million
Q4 2020 Feb 25, 2021	BUY	$19.0 - $32.63 $2.18 Million - $3.74 Million	114,530 New	114,530 $3.54 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.